Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Jan;19(1):77-83.
doi: 10.1007/s00784-014-1221-6. Epub 2014 Mar 18.

Impact of Orally Administered Lozenges With Lactobacillus Rhamnosus GG and Bifidobacterium Animalis Subsp. Lactis BB-12 on the Number of Salivary Mutans Streptococci, Amount of Plaque, Gingival Inflammation and the Oral Microbiome in Healthy Adults

Affiliations
Free PMC article
Randomized Controlled Trial

Impact of Orally Administered Lozenges With Lactobacillus Rhamnosus GG and Bifidobacterium Animalis Subsp. Lactis BB-12 on the Number of Salivary Mutans Streptococci, Amount of Plaque, Gingival Inflammation and the Oral Microbiome in Healthy Adults

Aino Toiviainen et al. Clin Oral Investig. .
Free PMC article

Abstract

Objectives: The aim was to evaluate the effects of orally administered Lactobacillus rhamnosus GG (LGG) and Bifidobacterium animalis subsp. lactis BB-12 (BB-12) on the number of salivary mutans streptococci (MS), amount of plaque, gingival inflammation and the oral microbiota in healthy young adults.

Materials and methods: The study was a randomised, controlled, double-blind trial. Healthy volunteers used lozenges containing a combination of LGG and BB-12 (test group, n = 29) or lozenges without added probiotics (control group, n = 31) for 4 weeks. At baseline and at the end of the test period, the plaque index (PI) and gingival index (GI) were determined, and stimulated saliva was collected. The microbial composition of saliva was assessed using human oral microbe identification microarray (n = 30). MS and lactobacilli (LB) were plate cultured.

Results: The probiotic lozenge decreased both PI and GI (p < 0.05) while no changes were observed in the control group. However, no probiotic-induced changes were found in the microbial compositions of saliva in either group.

Conclusions: The probiotic lozenge improved the periodontal status without affecting the oral microbiota.

Clinical relevance: Short-term consumption of LGG and BB-12 decreased the amount of plaque which was associated with a clinical impact: a decrease in gingival inflammation.

Figures

Fig. 1
Fig. 1
Individual HOMIM profiles for 27 selected predominant microbes representing the oral microbiota of the 15 subjects of the probiotic group at baseline and after 4-week use of the probiotic lozenge. The color intensity reflects relative proportions of the species present in the sample

Similar articles

See all similar articles

Cited by 12 articles

See all "Cited by" articles

References

    1. Isolauri E, Salminen S. Probiotics: use in allergic disorders: a Nutrition, Allergy, Mucosal immunity, and Intestinal microbiota (NAMI) research group report. J Clin Gastroenterol. 2008;42:S91–S96. doi: 10.1097/MCG.0b013e3181639a98. - DOI - PubMed
    1. Floch MH, Walker WA, Madsen K, Sanders ME, Macfarlane GT, Flint HJ, Dieleman LA, Ringel Y, Guandalini S, Kelly CP, Brandt LJ. Recommendations for probiotic use—2011 update. J Clin Gastroenterol. 2011;45:S168–S171. doi: 10.1097/MCG.0b013e318230928b. - DOI - PubMed
    1. Kumpu M, Kekkonen RA, Kautiainen H, Järvenpää S, Kristo A, Huovinen P, Pitkäranta A, Korpela R, Hatakka K. Milk containing probiotic Lactobacillus rhamnosus GG and respiratory illness in children: a randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr. 2012;66:1020–1023. doi: 10.1038/ejcn.2012.62. - DOI - PubMed
    1. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics. 2005;115:5–9. - PubMed
    1. Taipale T, Pienihäkkinen K, Isolauri E, Larsen C, Brockmann E, Alanen P, Jokela J, Söderling E. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br J Nutr. 2011;105:409–416. doi: 10.1017/S0007114510003685. - DOI - PubMed

Publication types

LinkOut - more resources

Feedback